Purpose of the development: E Landomycin drug intended for use in medicine as an antitumor polyketide antibiotic.

Recommended application field: Medicine.

Advantages over analogues: Highly effective new anti-cancer drug.

The development stage readiness: Ready for application

Description of the development:
()
Landomycin E - new antitumor polyketide antibiotic family angutsiklinov synthesized by Streptomyces . Antitumor effect landomycin E shown in 60 cancer cell lines at the National Cancer Institute, USA ( g.Betezda ) . The greatest sensitivity to the antibiotic showing leukemia cells . Landomycin E in cancer cells is a typical programmed death (apoptosis ) in a dose of 1.7 mcg / ml. Its exhibits antibiotic activity against cancer cells and multidrug resistance , including resistance to doxorubicin. Landomycin E inherent weak mutagenic and cytotoxic action of the average . The biotechnology obtain landomycin E by fermentation of a high strain of actinomycetes Streptomyces globisporus 1912-3 in an optimal environment . Laboratory regulations .

Information about newness of the development:

ноу-хау--
1 шт.

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Licence's sale
Technological document's sale
Combinated reduction to industrial level
Creation of joint enterprise

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua